Download PDF
CC BY-NC-ND 4.0 · Journal of Coloproctology 2022; 42(02): 120-125
DOI: 10.1055/s-0041-1741323
Original Article

Expression Levels of the CA9, WT1, and PRAME Genes and Genotyping-Associated Antigens for the Diagnosis and Prognosis of Colorectal Cancer

Tabark S Jassim 
1   Prosthodontic Technology Department, Dijlah University College, Baghdad, Iraq
› Author Affiliations Financial support The authors have no sources of funding to declare.
› Further Information
   Permissions and Reprints

Abstract

Background Colorectal cancer (CRC) is the third most prevalent type of cancer worldwide, and is one of the major health problems in Asia, Africa, Europe, and America. The tumor antigens recently are of interesting indicators as diagnostic and prognostic tools. The aim of the present study is to detect the expression levels of carbonic anhydrase IX (CA9), the Wilms tumor gene (WT1), and the preferentially expressed antigen in melanoma (PRAME) in the peripheral blood of CRC patients in comparison with healthy controls.

Methods A prospective case-control study of CRC patients was conducted. We included 25 newly-diagnosed CRC eligible patients and obtained peripheral blood samples of them as well as 10 blood samples from the control group. All samples were then submitted to deoxyribonucleic acid (DNA) extraction and a molecular study through real-time polymerase chain reaction (PCR).

Results The CRC group consisted of 15 (60%) female and 10 (40%) male patients with a mean age of 50.52 ± 9.8 years, while the control group included 4 (40%) female and 6 (60%) male patients with a mean age of 47.7 ± 7.9 years. The CRC group, 24 (96%) of patient samples were CA9-positive with strong statistically significant differences (p < 0.00001; sensitivity: 96%; specificity: 90%). Regarding the WT1 gene, there were 11 (44%) positive samples in the CRC group, with no statistically significant differences (p = 0.055; sensitivity: 44%; specificity: 90%). The PRAME gene was positive in 9 (36%) samples in the CRC group, with no statistically significant differences (p = 0.357; sensitivity: 36%; specificity: 80%. Among CA9 (24 patients; 96%) of patients with CRC expressed positive results, in WT1 11(91.6%) CRC patients expressed gene, and in PRAME gene, 9 patients with CRC (81.8%) expressed positive results.

Conclusion Overexpression of the CA9 gene in CRC of high sensitivity and specificity to be used as a tool to discriminate CRC from benign associate with high accuracy compare to WT1 and PRAME genes.

Keywords

colorectal cancer - tumor-associated antigens - real-time polymerase chain reaction - CA9 - WT1 - PRAME


Publication History

Received: 07 August 2021

Accepted: 25 October 2021

Article published online:
10 December 2021

© 2021. Sociedade Brasileira de Coloproctologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • References

  • 1 Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68 (06) 394-424
    CrossrefPubMedGoogle Scholar
  • 2 Alshewered AS, Al-Naqqash MA. Rectal cancer and chemoradiation in Iraq: systematic review and meta-analysis. J Coloproctol (Rio J) 2019; 39: 309-318
    Article in Thieme ConnectGoogle Scholar
  • 3 Alrubaia AMM, Al-Naqqash MA, Alshewered AS. Epidemiological, and prognostic single-center study of anal carcinoma. J Coloproctol (Rio J) 2020; 40 (03) 202-208
    Article in Thieme ConnectGoogle Scholar
  • 4 Alhilfi HSQ, Almohammadawi KOM, Alsaad RKA. et al. Colorectal cancer epidemiology and clinical study in Misan. J Coloproctol (Rio J) 2019; 39 (02) 159-162
    Article in Thieme ConnectGoogle Scholar
  • 5 Thiry A, Dogné JM, Masereel B, Supuran CT. Targeting tumor-associated carbonic anhydrase IX in cancer therapy. Trends Pharmacol Sci 2006; 27 (11) 566-573
    CrossrefPubMedGoogle Scholar
  • 6 Wykoff CC, Beasley NJ, Watson PH. et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 2000; 60 (24) 7075-7083
    PubMedGoogle Scholar
  • 7 Talvinen K, Tuikkala J, Grönroos J. et al. Biochemical and clinical approaches in evaluating the prognosis of colon cancer. Anticancer Res 2006; 26 (6C): 4745-4751
    Google Scholar
  • 8 Stauss HJ, Thomas S, Cesco-Gaspere M. et al. WT1-specific T cell receptor gene therapy: improving TCR function in transduced T cells. Blood Cells Mol Dis 2008; 40 (01) 113-116
    CrossrefPubMedGoogle Scholar
  • 9 Algar E. A review of the Wilms' tumor 1 gene (WT1) and its role in hematopoiesis and leukemia. J Hematother Stem Cell Res 2002; 11 (04) 589-599
    CrossrefPubMedGoogle Scholar
  • 10 Oji Y, Ogawa H, Tamaki H. et al. Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Jpn J Cancer Res 1999; 90 (02) 194-204
    CrossrefPubMedGoogle Scholar
  • 11 Inoue K, Sugiyama H, Ogawa H. et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994; 84 (09) 3071-3079
    CrossrefPubMedGoogle Scholar
  • 12 Loeb DM, Evron E, Patel CB. et al. Wilms' tumor suppressor gene (WT1) is expressed in primary breast tumors despite tumor-specific promoter methylation. Cancer Res 2001; 61 (03) 921-925
    PubMedGoogle Scholar
  • 13 Miyoshi Y, Ando A, Egawa C. et al. High expression of Wilms' tumor suppressor gene predicts poor prognosis in breast cancer patients. Clin Cancer Res 2002; 8 (05) 1167-1171
    PubMedGoogle Scholar
  • 14 Oji Y, Miyoshi S, Maeda H. et al. Overexpression of the Wilms' tumor gene WT1 in de novo lung cancers. Int J Cancer 2002; 100 (03) 297-303
    CrossrefPubMedGoogle Scholar
  • 15 Ueda T, Oji Y, Naka N. et al. Overexpression of the Wilms' tumor gene WT1 in human bone and soft-tissue sarcomas. Cancer Sci 2003; 94 (03) 271-276
    CrossrefPubMedGoogle Scholar
  • 16 Oji Y, Inohara H, Nakazawa M. et al. Overexpression of the Wilms' tumor gene WT1 in head and neck squamous cell carcinoma. Cancer Sci 2003; 94 (06) 523-529
    CrossrefPubMedGoogle Scholar
  • 17 Epping MT, Bernards R. A causal role for the human tumor antigen preferentially expressed antigen of melanoma in cancer. Cancer Res 2006; 66 (22) 10639-10642
    CrossrefPubMedGoogle Scholar
  • 18 Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16 (03) 1215
    CrossrefPubMedGoogle Scholar
  • 19 Korinek V, Barker N, Morin PJ. et al. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science 1997; 275 (5307): 1784-1787
    CrossrefPubMedGoogle Scholar
  • 20 Radhi AA, Muslim OT, Abdlmaged MA. Epidemiological distribution of colorectal cancer in AL-Diwaniyah province, Iraq: an observational study. J Pharm Sci & Res. 2018; 10 (07) 1758-1760
    Google Scholar
  • 21 Alsafi RAR, Metib NJ, Hameedi AD. et al. The Clinical and Pathological Characteristics of Colorectal Cancer in Young Age Group in Karbala Province/ Iraq. Karbala J Med. 2018; 11 (02) 4025-4031
    Google Scholar
  • 22 Khalil KH, Al-Hassawi BA, Abdo JM. Histopathological evaluation of colorectal carcinoma. Duhok Medical Journal. 2018; 12 (02) 45-68
    CrossrefGoogle Scholar
  • 23 Al Dahhan SA, Al Lami FH. Epidemiology of Colorectal Cancer in Iraq, 2002-2014. Gulf J Oncolog 2018; 1 (26) 23-26
    PubMedGoogle Scholar
  • 24 https://www.nice.org.uk/ The National Institute for Health and Care Excellence/guidance/cg131/ colorectal cancer diagnosis and management/ 2014
    PubMed
  • 25 http://publications.iarc.fr/ The International Agency for Research on Cancer/Non-Series-Publications/World cancer report/ 2014
    PubMed
  • 26 Wang MJ, Ping J, Li Y. et al. The prognostic factors and multiple biomarkers in young patients with colorectal cancer. Sci Rep 2015; 5: 10645
    CrossrefPubMedGoogle Scholar
  • 27 Feitosa MR, de Oliveira THGF, Kondo BRP. et al. The epidemiological and clinical features of familial adenomatous polyposis in Ribeirão Preto. J Coloproctol (Rio J) 2013; 33 (03) 126-130
    Article in Thieme ConnectGoogle Scholar
  • 28 Giatromanolaki A, Koukourakis MI, Sivridis E. et al. Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res 2001; 61 (21) 7992-7998
    PubMedGoogle Scholar
  • 29 Korkeila E, Talvinen K, Jaakkola PM. et al. Expression of carbonic anhydrase IX suggests poor outcome in rectal cancer. Br J Cancer 2009; 100 (06) 874-880
    CrossrefPubMedGoogle Scholar
  • 30 Driessen A, Landuyt W, Pastorekova S. et al. Expression of carbonic anhydrase IX (CA IX), a hypoxia-related protein, rather than vascular-endothelial growth factor (VEGF), a pro-angiogenic factor, correlates with an extremely poor prognosis in esophageal and gastric adenocarcinomas. Ann Surg 2006; 243 (03) 334-340
    CrossrefPubMedGoogle Scholar
  • 31 Oji Y, Yamamoto H, Nomura M. et al. Overexpression of the Wilms' tumor gene WT1 in colorectal adenocarcinoma. Cancer Sci 2003; 94 (08) 712-717
    CrossrefPubMedGoogle Scholar
  • 32 Oberthuer A, Hero B, Spitz R, Berthold F, Fischer M. The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome. Clin Cancer Res 2004; 10 (13) 4307-4313
    CrossrefPubMedGoogle Scholar
  • 33 Huang Q, Li L, Lin Z. et al. Identification of Preferentially Expressed Antigen of Melanoma as a Potential Tumor Suppressor in Lung Adenocarcinoma. Med Sci Monit 2016; 22 (22) 1837-1842
    CrossrefPubMedGoogle Scholar
  • 34 Wadelin F, Fulton J, McEwan PA, Spriggs KA, Emsley J, Heery DM. Leucine-rich repeat protein PRAME: expression, potential functions and clinical implications for leukaemia. Mol Cancer 2010; 9: 226
    CrossrefPubMedGoogle Scholar